Study of AHB-137 for chronic hepatitis B
Treatments studied
Part of Digestive system, Infections clinical trials.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had chronic hepatitis B for at least 6 months
- You are between 18 and 65 years old
- You have a positive test for hepatitis B surface antigen (HBsAg) or HBV DNA
- Your liver function and virus levels meet study limits
- You have not had other serious liver diseases or infections
- You are willing to use effective birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injection called AHB-137 in people with chronic hepatitis B who have never received antiviral treatment. The goal is to see if it can help reduce the hepatitis B virus in the body and improve liver health.
This study tests a new injection called AHB-137 combined with other hepatitis B drugs. It aims to see if the combination can better control the virus in people with chronic hepatitis B who are already on antiviral pills.
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
This study tests a new drug, GST-HG131, for people with chronic hepatitis B who are already on stable treatment. It aims to see if the drug is safe and reduces the virus further.
This study tests how a new investigational drug called AHB-137 moves through your body and affects safety in people with mild-to-moderate liver problems compared to people with normal liver function. The goal is to understand if the drug works safely in people whose livers don't work as well as they should.
This study follows participants with chronic hepatitis B who previously responded to the drug AHB-137. The goal is to track long-term health and safety after their treatment.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.